NCT05802810View on ClinicalTrials.gov

The Mass Balance Study of [14C]JT001

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

March 18, 2023

Primary Completion Date

September 27, 2023

Study Completion Date

September 27, 2023

Conditions
Healthy Subjects
Interventions
DRUG

[14C]JT001

Subjects will receive approximately 300 mg/100 µCi of \[14C\]JT001 orally.

Trial Locations (1)

215006

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
collaborator

Sponsor GmbH

OTHER

lead

Shanghai Vinnerna Biosciences Co., Ltd.

INDUSTRY